Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2019

View Archived Issues

To sleep, perchance to clean: Sleep-inducing protein plays role in immunity

Stretching taxes CRISPR's abilities

Typhus vaccination broadly alters immune response

Sacituzumab govitecan demonstrates clinical activity in patients with metastatic urothelial cancer

Novel SIRT7 inhibitor demonstrates promising safety and efficacy in preclinical cancer models

Nektar Therapeutics presents preliminary data from phase Ib/II REVEAL study

Janssen reports phase I/II data for cetrelimab in patients with advanced cancers

Preliminary results from phase II study of lifileucel in metastatic melanoma

Adagene announces platform evaluation with Celgene

Verona reports part one data from phase II trial of DPI formulation of ensifentrine in COPD

Bristol-Myers Squibb presents lysophospholipid S1P1 receptor agonists

Arrowhead opens enrollment in phase I study of ARO-APOC3

Vyera Pharmaceuticals patents protozoal DHFR inhibitors

Single chain antibody against TDP-43 shows therapeutic potential in murine models of ALS/FTD

Vaccine targets generated by cell-free protein synthesis limit P. gingivalis-elicited oral bone loss

The Vanderbilt University discloses muscarinic M4 receptor antagonists

Rodin Therapeutics identifies HDAC inhibitors

Eli Lilly and Company synthesizes PDE1 inhibitors

Early trial data reported for anti-TIM-3 antibody LY-3321367 with anti-PD-L1 antibody LY-3300054

Funding to support exploration of TXA-127 for epidermolysis bullosa

Healx partners with Boston Children's Hospital to advance drug discovery in Barth syndrome

Lupus Therapeutics collaborates with Takeda on phase I trial of TAK-079 for SLE

OncBioMune initiates phase II study of Proscavax in localized prostate cancer

BirchBioMed initiates proof-of-concept study with FS-2 to reduce keloid scars

Apellis resumes enrollment in phase III geographic atrophy trials of APL-2

Axsome initiates phase III trial of AXS-07 for acute treatment of migraine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...